TREVI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS AND CORPORATE UPDATE
March 16, 2020 08:00 ET
|
Trevi Therapeutics
Enrollment in PRISM Study Progressing - Sample Size Re-estimation Planned for mid-2020 Expect to Report Top-Line Data in both PN and IPF-Cough Trials in Second Half of 2020 Cash Position of $57.3...
Trevi Therapeutics to Present at SVB Leerink Healthcare Conference
February 20, 2020 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Trevi Therapeutics Announces Election of James V. Cassella, Ph.D. to Board of Directors
February 18, 2020 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER...
Trevi Therapeutics Announces Third Quarter 2019 Financial Results and Recent Business Developments
November 14, 2019 16:05 ET
|
Trevi Therapeutics
Advancement of Nalbuphine ER in Clinical Development for Three Indications Cash Position of $63.5 Million Expected to Fund Operations Through At Least Q1 2021 NEW HAVEN, Conn., Nov. 14, 2019 ...
Trevi Therapeutics to Present at Stifel Healthcare Conference
November 13, 2019 17:01 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Trevi Therapeutics to Participate in Panel Discussion at BTIG Pain / Pruritus Management Forum
September 05, 2019 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
Trevi Therapeutics Announces Second Quarter 2019 Financial Results and Recent Business Developments
August 12, 2019 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Conference
June 18, 2019 16:05 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., June 18, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
Trevi Therapeutics Announces First Quarter 2019 Financial Results and Recent Business Developments
June 13, 2019 16:09 ET
|
Trevi Therapeutics
Raised $70 Million in Gross Proceeds from Initial Public Offering and Concurrent Private Placement Initiated Phase 2 Clinical Trial for Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis...
Trevi Therapeutics Announces Pricing of Initial Public Offering
May 07, 2019 13:22 ET
|
Trevi Therapeutics
NEW HAVEN, Conn., May 07, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to...